Study register · detailSystematic Review · Crohn Disease · 2015
Systematic Review of Complementary and Alternative Medicine Treatments in Inflammatory Bowel Diseases
Langhorst et al.·Journal of Crohn's and ColitisImpact 0.9
MixedGRADEHigh198 citations
Samplek = 39 Studien
DurationDatabase search through March…
ControlControl groups from included RCTs/CTs
EndpointDisease activity
Blindingunklar
DesignSystematic Review
”Key finding
Best evidence for herbal therapy (Plantago ovata and curcumin in UC maintenance therapy, wormwood in CD), mind-body therapy and acupuncture, but overall low number of studies and heterogeneous methodological quality.
Summary
Systematic review on complementary and alternative medicine in IBD (Crohn's disease and ulcerative colitis); k=39 studies (26 RCTs + 3 CTs on phytotherapeutics, 7 RCTs on mind/body interventions, 2 RCTs on acupuncture, 1 RCT on Trichuris suis). Evaluated cannabis, among others, as a phytotherapeutic. Best evidence for Plantago ovata and curcumin in UC maintenance therapy, wormwood in CD, mind/body therapy in UC, acupuncture in UC and CD. Heterogeneous methodological quality (Cochrane Risk of Bias).
P
PopulationPatients with inflammatory bowel disease (Crohn's disease and ulcerative colitis)
I
InterventionComplementary and alternative medicine (CAM), including phytotherapeutics (incl. cannabis), mind-body interventions, acupuncture
C
ControlControl groups from included RCTs/CTs (placebo or active control)
O
OutcomeBest evidence for Plantago ovata and curcumin (UC maintenance therapy), wormwood (CD), mind-body therapy (UC) and acupuncture (UC/CD); heterogeneous risk structure of the studies
Confidence in the evidence
Very lowLowModerateHigh
High
The highest of four GRADE levels, the effect estimate is very reliable.
Objective: We performed a systematic review for Complementary and Alternative Medicine [CAM] as defined by the National Institute of Health in Inflammatory Bowel Disease [IBD], ie Crohn's disease [CD] and ulcerative colitis [UC], with the exception of dietary and nutritional supplements, and manipulative therapies.
Methods: A computerized search of databases [Cochrane Library, Pubmed/Medline, PsychINFO, and Scopus] through March 2014 was performed. We screened the reference sections of original studies and systematic reviews in English language for CAM in IBD, CD and UC. Randomized controlled trials [RCT] and controlled trials [CT] were referred and assessed using the Cochrane risk of bias tool.
Results: A total of: 26 RCT and 3 CT for herbal medicine, eg aloe-vera gel, andrographis paniculata, artemisia absinthium, barley foodstuff, boswellia serrata, cannabis, curcumin, evening primrose oil, Myrrhinil intest(R), plantago ovata, silymarin, sophora, tormentil, wheatgrass-juice and wormwood; 1 RCT for trichuris suis ovata; 7 RCT for mind/body interventions such as lifestyle modification, hypnotherapy, relaxation training and mindfulness; and 2 RCT in acupuncture; were found. Risk of bias was quite heterogeneous. Best evidence was found for herbal therapy, ie plantago ovata and curcumin in UC maintenance therapy, wormwood in CD, mind/body therapy and self-intervention in UC, and acupuncture in UC and
Cd. Conclusions: Complementary and alternative therapies might be effective for the treatment of inflammatory bowel diseases; however, given the low number of trials and the heterogeneous methodological quality of trials, further in-depth research is necessary.